Plus, a deep discount in the private warehouse club sector, a Starbucks competitor Citi sees as a sharp share gainer, and a little-known stock poised to solve a “critical” problem.
Plus, William Blair’s memory “supercycle” winner, a stock Morgan Stanley says has “ongoing execution issues”, Netflix’s new deal, the top IPOs of tomorrow, and more.
Plus, why Wells Fargo sees a turnaround for DraftKings, Morgan Stanley’s casualty of the “grocery wars”, and more.
Plus, Oppenheimer’s 'golden opportunity for a breakout', why Freedom Capital believes Venezuela oil enthusiasm is 'unjustified', a big bank going full crypto, and more.
Plus, a doubled price target from Aletheia, potential beneficiaries of the latest tariff delay, and much more.
We reviewed outlooks from a dozen bulge-bracket banks, asset managers, and global investment firms to identify the most useful takeaways for active investors like you.
Plus, the mid-cap software stock KeyBanc was wrong about, Goldman Sachs’ semiconductor double-downgrade, and much more.
Plus, dual double-downgrades, a crypto firm with 130% implied upside, and much more.
The secret sauce behind silver’s rally, Wells Fargo’s new pick for AI “super-cycle” leader, Huber Research’s grim view on the Netflix-WBD deal, and much more.
An income investment for the new rate environment, a massive IPO announcement, an 'overdone' AI selloff, and more.
A beaten-down sector quietly being transformed by AI, a firm 'uniquely positioned' within the Trump administration, and much more.
The energy tail risk no one’s talking about, why a retail giant got double-downgraded, a candidate for the next IPO pop, and more.
This week in Street Sheet Research: a six-week market rally hits a wall amid AI fatigue, Datadog barks back with post-earnings upgrades, and the U.S. redraws its critical minerals map. Plus, what Polymarket’s long-awaited U.S. debut could mean for prediction markets everywhere.
Plus, an attractive opportunity amid a 'minefield for investors', a slew of price target hikes across the crypto sector, and more.
Plus, a biotech with 'potentially game-changing' trial results, the 'too far, too fast' rally you might still be betting on, and more.
Plus, who could win from OPEC’s latest production target hike, Baird’s pick for the “AI juggernaut for the information age”, and more.
Plus, why markets shrugged off news of the shutdown, sweeping pharmaceutical developments in DC, and dueling analyst calls on Apple
A sudden development in the genetic-editing sector, another wild week for Nvidia, and much more.
A bold Nvidia investment that didn’t grab headlines, a paradigm shift for commodity markets, and more.
Fed cut odds shift, EchoStar–SpaceX deal, Nike/Dick’s calls, BofA downgrade, pharma pressure, streaming shakeup.
